INF Medical Committee
Terms of Reference

The INF Medical Committee (MC) is authorised by the INF Board of Directors to conduct its business in accordance with the Terms of Reference as set out below. The Board of Directors may review these at any time and, when appropriate, revise in accordance with the changing requirements of INF. The MC is advisory and will make recommendations to the INF Board to assist INF achieve its vision, values and strategic goals as outlined in the Strategic Plan, with respect to anti-doping and the health and wellbeing of the participants of netball.

1. Composition and Membership:
   1.1. The Committee will consist of up to four members; one of whom must be a different gender.
   1.2. The Board will formally approve composition of the MC and may appoint additional members to the MC or remove and replace members of the MC by resolution. Members may withdraw from membership by written notification to the Board.
   1.3. The Committee will consist of:
      1.3.1. A chair;
      1.3.2. Two or more individuals who are not directors or management, with relevant medical expertise to assist the panel to fulfil its functions.
      1.3.3. Appointments to the committee shall be for a period of up to four years, which may be extended to three four year periods, provided the Board so agree.
   1.4. The Committee may seek additional professional expertise to assist in fulfilling its functions.

2. Responsibilities
   2.1. The responsibility of the Committee is to help the Board carry out its due diligence function related to all Medical, Health and Anti-Doping areas relevant to sport by:
      2.1.1. Advising and guiding the INF Board and Members on medical issues specific to netball to ensure timely and informed decision-making.
      2.1.2. Determining and recommending policies, rules and regulations and developing related norms and standards for INF.
      2.1.3. Taking responsibility for the implementation of all technical aspects of the World Anti-Doping Code and the International Standards, including the work of the INF Therapeutics Use Exemption Committee.
      2.1.4. Ensuring the adoption and implementation of relevant national and international standards applicable to the sport of netball by INF and its
affiliates, including at the Netball World Cup and other international events sanctioned by INF.

2.1.5. Providing representation for INF at selected national and international forums on medical, health and anti-doping issues, as requested.

2.1.6. Providing management strategies for International and Public Health measures, specific to each region.

2.1.7. Conducting and supporting research to provide INF with advice on future trends, opportunities and direction.

2.1.8. Establishing and maintaining linkages with other Medical and Anti-Doping Organizations, Commissions and Committees.

2.2. The priority areas are:

2.2.1. Adoption and implementation of the WADA Code, International Standards, INF Anti-Doping Policy and all related rules, regulations and guidelines.

2.2.2. Development of policies, norms and standards for medical and health areas of sports relevant to netball.

2.2.3. Information provision and education of INF and affiliates on medical, health and anti-doping issues relevant to netball, to encompass alternative modalities, including sports medicine, biomechanics, physiology applied to sports, nutrition and all sciences linked to sports.

2.2.4. Generating research specifically relating to medicine and science in netball

3. Operating & Reporting Procedure

3.1. The Committee will be required to operate according to the procedure agreed by the MC at the start of their term of office and approved by the Board.

3.2. The MC will report to the Board at each Board meeting and as requested by the Board.

3.3. Discussions and decisions taken by the MC must happen in a transparent and efficient way via the appropriate means of communication in accordance with any deadlines set by the Board.

3.4. Any decisions circulated by email require a 50% majority support from all MC members with the Chair, where necessary, having the casting vote.

3.5. Any decisions at MC meetings will require a 50% majority of all those MC members present with the Chair, where necessary, having the casting vote.

3.6. Non response within the required timeframe to a request for a decision will be regarded as support for the decision.

4. Meetings

4.1. The MC may hold any meetings as it decides are necessary to fulfil its duties. If appropriate these may by teleconference or by videoconference.

4.2. Proxy attendance shall not be permitted

4.3. The CEO or a representative of the Secretariat will be present at any meeting.

4.4. Meeting agendas will be prepared by the Chair in conjunction with the CEO and circulated to all members of the MC no later than a week before the meeting.

4.5. Minutes will be taken by the CEO or nominated person attending the meeting, which may include a member of the MC.

4.6. Minutes of all meetings will be circulated to the Board and MC members.
4.7. A quorum of a minimum of 50% of the MC shall be required for all meetings
4.8. In the absence of the Chair, he/she will appoint a Deputy.

5. **Budget and spending authority**
   5.1. Meeting expenses will be covered in accordance with INF’s expenses policy.
   5.2. Any other expenses must be approved through the CEO in accordance with INF’s financial policy and budgets.

6. **Assessment and Evaluation of the Committee’s Performance**
   6.1. The Committee will, at least once in each financial year:
      6.1.1. Have its performance assessed in the method prescribed by the Board and having regard to the requirements of this Terms of Reference; and
      6.1.2. Determine the goals and objectives of the Committee for the forthcoming year and review the Terms of Reference in light of any modifications to the Committee’s goals and objectives.